Hospitalization and Health Service Resource Utilization in Emergency **Department Cases of Diabetic Foot Infections: A Nationally-Representative Analysis**

Matthew C. Dickson, PharmD, MS¹; Grant H. Skrepnek, PhD¹ The University of Oklahoma Health Sciences Center, Oklahoma City, OK, US¹

Background

An estimated 34.1 million adults in the United States (US) have been diagnosed with diabetes, with 15-35% potentially developing a diabetic foot ulcer (DFU) in their lifetime.^{1,2} Diabetic foot infections (DFI) occur in more than half of DFUs and are associated with substantial morbidity and mortality.²

Objective

The objective of this study was to assess hospitalization and health resource utilization associated with DFI-related visits within emergency departments (ED) in the US.

Methods

Design & Analysis: Nationally-representative, crosssectional, historical cohort analysis using bivariable generalized linear model framework

Database:

 CDC's National Hospital Ambulatory Medical Care Survey (NHAMCS) (2015-2019)

Inclusion Criteria:

• Adults \geq 18 years with a diagnosis of Type 1 or Type 2 diabetes mellitus with or without a diagnosis of DFI. DFI diagnosis determined by ICD-9-CM or ICD-10-CM diagnosis codes.³ An expanded DFI criteria also included cases determined via reason for visit codes.⁴

Outcomes:

- 72-hour ED revisit; hospital admission; and inpatient length of stay
- Medication classes of drugs prescribed/used in ED **Covariates:**
- Demographics (age, sex, race, primary insurance coverage); health system characteristics (rural/urban physician practice; geographic region; practitioner level); clinical characteristics (Deyo-Charlson Comorbidity Index, number of chronic conditions, Emergency Severity Index); year

	DFI ^a	DFI – Expanded Criteria ^b	Diabetes	Overall
	(n= 551,224)	(n= 987,112)	(n= 80,014,345)	(n = 540,401,920)
Demographics				
Age (mean±SD)	56.3 ± 12.3*	54.8 ± 13.1***	60.0 ± 14.2	47.3 ± 16.6
Male (%)	60.4	58.9*	44.5	42.7
Race(%)				
White	75.1	73.0	69.9	72.6
Black	24.1	26.2	26.2	24.1
Other	0.7	0.8*	4.0	3.3
Ethnicity (%)				
Hispanic	10.1	14.1	13.4	13.3
Primary Insurance Coverage (%)				
Private Insurance	20.0	21.1	21.0	28.4
Medicare	18.8	26.3	22.5	29.4
Medicaid	35.3	32.9	37.3	21.7
Dual	11.0	8.0	11.8	5.5
Other	14.9	11.7	7.4	15.1
Health System Characteristics			1.4	
Rural Physician Practice (%) [†]	10.5	12.2	16.4	16.0
Geographic Region (%)	10.5	12.2	10.4	10.0
Northeast	17.2	15.2	14.6	16.2
Midwest	25.1	27.4	23.4	22.3
South		31.8	42.0	
	28.9			40.1
West	28.8	25.6	20.0	21.3
hysician Assistant or Nurse Practitioner ^c	8.7	9.1	8.3	11.1
Clinical Characteristics	40+40	4.0.1.4.0	0.0 + 4.0	07440
Deyo-Charlson Comorbidity Index, mean ±SD	1.9 ± 1.3	1.8 ± 1.2	2.0 ± 1.2	0.7 ± 1.0
One Chronic Condition	63.3	62.1*	50.1	20.5
Two or More Chronic Conditions	36.7	37.9*	49.9	14.9
Emergency Severity Index				7.0
Level 1 (Immediate)	8.5	9.3	8.3	7.6
Level 2 (Emergent)	8.1***	6.6***	31.0	27.7
Level 3 (Urgent)	38.0	34.9	28.0	27.9
Level 4 (Semi-Urgent)	10.3	11.0	5.3	7.6
Level 5 (Non-Urgent)	35.2	38.2*	27.4	29.3
Sepsis (%)	11.8**	8.0**	1.6	0.8
/ear (%)				
2015	40.4***	26.2*	18.2	19.5
2016	28.1	23.8	19.4	21.0
2017	4.7**	15.3	20.5	19.5
2018	12.7	14.7	19.6	18.6
2019	14.1	19.9	22.3	21.5
lealth Service Outcomes				
	11.4*	8.2	4.7	4.2
Seen in ED in Last 72 Hours (%)				
	49.0*** 7.6 ± 5.2	37.6**	25.4 5.7 ± 4.6	13.9 5.3 ± 4.2





The UNIVERSITY of OKLAHOMA College of Pharmacy

Results

Descriptive statistics:

- An estimated 80.6 million ED visits included a diabetes diagnosis, with 551,224 DFI cases (0.7%). The expanded DFI criteria included 987,112 cases (1.2%).
- DFI cases were significantly younger relative to diabetes-only cases (56.7 \pm 11.6 years vs. 60.0 \pm 13.5, p=0.046), and involved 60.4% males and 75.1% white
- Sepsis was present in a significantly higher proportion of DFI cases than cases with diabetes-only (11.8% vs. 1.6%, p=0.001).
- Anti-infective medications were the most frequentlyprescribed medication class in 88.2% of DFI cases, significantly higher than 23.3% of diabetes-only cases (p<0.001).

Outcomes:

- DFI ED visits involved significantly:
 - More 72-hour ED revisits (11.4% vs. 4.7%, p=0.029);
 - More Hospital admissions (49.0% vs. 25.4%, p<0.001);
 - Higher odds of 72-hour ED revisit (2.6 times higher, p=0.029);
 - And higher odds of hospital admission (2.8 times higher, p<0.001).
- Length of stay was not significantly different between groups (p=0.131) and averaged 7.6 ± 5.4 days for DFIs.
- In the expanded criteria, DFI cases did not significantly differ in 72-hour ED revisits but did have significantly longer lengths of stays (8.1 days vs. 5.7, p=0.044).
- In the expanded criteria, DFI cases were more frequently admitted to a hospital, having a 77% higher odds of any admission (p=0.005).

Limitations

- Long-term longitudinal analyses for readmissions are not feasible using CDC NHAMCS data.
- To retain confidentiality, the CDC NHAMCS dataset is fully de-identified and anonymized to define the unit analysis as the ED visit rather than the patient.
- Caution is warranted in generalizing findings to specific populations or health systems.

Conclusions

This nationally-representative study of DFI-related ED visits in the US observed a 2.6- and 2.8-times higher odds of 72-hour ED revisits and hospitalizations, respectively, for DFIs versus diabetes without foot complications. Further research should seek to assess and develop prevention and coordinated treatment interventions prior to the emergence of DFIs requiring ED care.

References

1. National Diabetes Statistics Report, 2020. Centers for Disease Control, CDC: Atlanta, GA; 2020. Internet: https://www.cdc.gov/diabetes/data/statisticsreport/index.html Accessed: December 9, 2020.

2. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367-2375.

3. Sohn MW, Budiman-Mak E, Stuck RM, Siddiqui F, Lee TA. Diagnostic accuracy of existing methods for identifying diabetic foot ulcers from inpatient and outpatient datasets. J Foot Ankle Res. 2010;3:27.

4. Schneider D, Appleton L, McLemore T. A reason for visit classification for ambulatory care. *Vital Health Stat 2.* 1979;78:i-63.

Disclosure

MCD and GHS disclose unrelated research grants from Janssen and Pfizer. GHS also discloses unrelated research grant from Otsuka.

This study was not funded by any organization.